Document is current
Any future updates will be listed below
-
Authors
Schneck, Emmanuel
Edinger, Fabian
Uhle, Florian
Markmann, Melanie
Hecker, Andreas
Weigand, Markus A.
Sander, Michael
Koch, Christian
-
Funding
Funding for this research was provided by:
Deutsches Zentrum für Infektionsforschung (TI 07.001_Schneck_00)
Justus-Liebig-Universität Gießen
- License Information
-
More Information
Article History
Received: 17 December 2021
Accepted: 30 July 2022
First Online: 3 August 2022
Competing interests
: ES, FE, MM, AH, MS, and CK declare that they have no competing interests. FU and MAW own as co-Inventors the Intellectual property of the sDLL1 ELISA for the diagnosis and risk stratification for fungal infections (EP17185036.5) and the use of sDLL1-1 for diagnosing severe infections (EP17198330.7). MAW is further a co-founder of Delta Theranostics GmbH. FU is Associate Director of Medical Affairs Europe of Inflammatix (Clinical Affairs, Burlingame, California, USA).
